LIQUID CRYSTALLINE DRUG DELIVERY SYSTEM FOR SUSTAINED RELEASE LOADED WITH AN ANTITUBERCULAR DRUG
Abstract
In present study, LCs were formulated and evaluate for desirable properties, Sonication conditions were firstly investigated to determine their effects on the morphological and dimensional characteristics of liquid crystals and optimized according probe sonication condition (Ultra Tarrux T25), liquid crystals with reproducible narrow particle size distribution and mean particle size of 168.0 ± 2.1 nm were obtained. The structure of the dispersed cubosomes was revealed by XRD (X-ray diffraction) and SEM (scanning electron microscopy) as a liquid crystalline phase. To overcome the dose frequency and increase drug loading rate, in vitro-dissolution, method, ultracentrifuge be firstly develop liquid crystals containing Rifampicin. The encapsulation efficiency determined by UV spectroscopy was 93.86 ± 0.11% and stability studies in pH 6.8 phosphate buffer solutions further confirmed that Rifampicin was successfully encapsulated in liquid crystals.
Keywords: Cubic phases, liquid crystals, GMO, Rifampicin, high speed homogenization (Ultra Tarrux T25), probe sonication.
DOI
https://doi.org/10.22270/jddt.v8i4.1719References
Kaufmann S.H. and McMichael, A.J., Annulling a dangerous liaison: vaccination strategies against AIDS and tuberculosis. Nature medicine, 2005; 11(4s):S33.
Sun Z., Zhang J., Song H., Zhang X., Li Y., Tian M., Liu Y., Zhao Y., Li C., Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates. International Journal of Tuberculosis Lung Disorders. 2010; 14:1436-1441.
Caminero J.A., Sotgiu G., Zumla A., Migliori G.B., Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. The Lancet Infectious Diseases. 2010; 10(9):621-629.
Pooja D., Tunki L., Kulhari H., Reddy B.B. and Sistla R., 2015. Characterization, biorecognitive activity and stability of WGA grafted lipid nanostructures for the controlled delivery of Rifampicin. Chemistry and physics of lipids, 193, pp.11-17..
Muller F., Salonen A. and Glatter O. Monoglyceride-based cubosomes stabilized by laponite: Separating the effects of stabilizer, pH and temperature. Colloids Surf A: Physico Eng Asp, 2010; 358:50-56.
Gaikwad P.P. and Desai M.T. Liquid crystalline phase and its pharma applications. Intl J Pharma Res Rev, 2013; 2:40-52.
Lai J., Chen J., Lu Y., Sun J., Hu F., Yin Z. and Wu W. Glyceratemonooleate/poloxamer 407 cubic nanoparticles as oral drug delivery systems I. In vitro evaluation and enhanced oral bioavailability of the poorly water soluble drug Simvastatin. AAPS PharmSci Tech, 2009; 10:960-966.
Chen Y., Ma P and Gui S. Cubic and hexagonal liquid crystals as drug delivery systems. BioMed Research International, 2014; 1-12
Omray L.K. Liquid crystals as novel vesicular delivery system: Review. Curr Trends TechnolSci, 2013; 2:347-353.
Fong W.K, Dong, Y.D and Boyd, B.J., Drug delivery in Lyotropic Liquid Crystals: Applications of X-ray scattering in pharmaceutical science, Langmuir Int. J. Pharm. 2011.
Guo C., Wang J., Cao F., Lee R.J. and Zhai G. Lyotropic liquid crystal systems in drug delivery. Drug Del Today, 2010; 15:1032-1040.
Shah M.H. and Paradkar A. Cubic liquid crystalline glycerylmonooleate matrices for oral delivery of enzyme. Intl J Pharma 2005; 294:161-171.
Spicer P.T. Progress in liquid crystalline dispersions: Cubosomes. CurrOpin Colloid Inter Sci, 2005; 10:274-279.
Worle G., Siekmann B. and Bunjes H. Effect of drug loading on the transformation of vesicular into cubic nanoparticles during heat treatment of aqueous monoolein/poloxamer dispersions. Euro J PharmaBiopharma, 2006; 63:128-133.
Boyd B.J., Whittaker D.V., Khoo S.-M. and Davey G. Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. Intl J Pharma 2006; 309:218-226.
Tilley A.J., Drummond C.J. and Boyd B.J. Disposition and association of the steric stabilizer Pluronic® F127 in lyotropic liquid crystalline nanostructured particle dispersions. J Colloid Inter Sci, 2013; 392:288-296.
Serpe, L., Catalano, M. G., Cavalli, R., Ugazio, E., Bosco, O., Canaparo, R., Muntoni, E., Frairia, R., Gasco, M. R., Eandi, M. and Zara, G. P. Cytotoxicity of anticancer drugs incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur. J. Pharm. Biopharm., 2004; 58:673– 80.
Tan S. W., Billa N., Roberts C. R. and Burleyc J. C. Surfactant effects on the physical characteristics of Amphotericin B-containing nanostructured lipid carriers. Colloids Surf. A: Physicochem. Eng. Aspects. 2010; 372:73– 9.
Siddique S., Khanam J. and Bigoniya P., Development of sustained release capsules containing “coated matrix granules of metoprolol tartrateâ€. Aaps Pharmscitech, 2010; 11(3):1306-1314.
Published
Abstract Display: 842 
PDF Downloads: 1131 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.